Roche's recent decision to return the rights to UCB’s anti-tau antibody bepranemab comes after a four-year investment in the Alzheimer's disease drug candidate, which was initially valued at up to $2 billion in milestones. This strategic move happens just before the release of phase 2a d
Additive manufacturing, commonly known as 3D printing, has emerged as a revolutionary technology within the biopharmaceutical industry, offering considerable benefits. One of the most compelling advantages of additive manufacturing is its potential to optimize cleanroom space through the
PureTech Health, a Boston-based biotechnology firm, employs an innovative "hub-and-spoke" model, centralizing resources and expertise to support various offshoot companies focused on specific therapeutic areas or drug-making technologies. This approach aims to merge the strengths of a
Quantum BioPharma Ltd., a biotech firm specializing in neurodegenerative and metabolic disorders, has recently taken legal action against CIBC World Markets and RBC Dominion Securities. The lawsuit, filed in the United States District Court for the Southern District of New York, claims that these
In a surprising move to address ongoing financial difficulties and strategic challenges, CVS Health has made a significant leadership change by replacing CEO Karen Lynch with David Joyner, head of Caremark. This transition underscores the pressing need for CVS to stabilize its operations and refine
Are Biopharma Companies Ready for Today's Regulatory Challenges? The biopharmaceutical sector is rapidly evolving, with companies constantly innovating to develop new treatments for a variety of diseases. However, navigating the regulatory landscape remains a significant challenge. Stricter
